Drug Trial Radar · NCT06805825
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Feb 3, 2025
Primary completion
Aug 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Novelty Nobility, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Conditions
- Gastrointestinal Stromal Tumors
- Small-cell Lung Cancer
- Adenoid Cystic Carcinoma
- Uveal Melanoma
- Neuroendocrine Tumors
- Chromophobe Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
Interventions
NN3201Drug
A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with Dose-limiting Toxicities:Time frame: 3 weeks
- Incidence of Adverse Events:Time frame: 1 year
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Michigan Hospitals
Ann Arbor, Michigan · Recruiting
Case Comprehensive Cancer Center
Cleveland, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.